Erectile Dysfunction and Cardiovascular Disease: Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors in Men With Both Conditions

Nehra, Ajay
February 2009
Mayo Clinic Proceedings;Feb2009, Vol. 84 Issue 2, p139
Academic Journal
Risk factors for cardiovascular disease and erectile dysfunction (ED) are similar, as might be expected given their shared etiologic and pathophysiologic origins, It is now generally accepted that most cases of ED result from a vascular disturbance of the endotheilum. Recent epidemiological studies have documented a strong association between ED and comorbid conditions such as hypertension, diabetes mellitus, and dysilpidemia. Phosphodiesterase type 5 (PDE5) inhibitors are recommended as first-line therapy for erection problems of all etiologies and seventies. The efficacy and safety of PDE5 Inhibitors In the general ED population is well documented and has been extensively reviewed. To examine the association between ED and vascular disorders in the context of current knowledge regarding PDE5 inhibitors, an electronic search was performed of articles published from January 2002 through April 2008 using the PubMed, EMBASE, and MEDLINE databases. Although preference was given to randomized, blinded, controlled clinical trials, data from retrospective studies were also reviewed when appropriate. This analysis revealed that the clinical evidence linking ED to future cardiovascular events is compelling, presenting physicians with a unique interventional opportunity to address underlying cardiovascular health concerns in men presenting with ED. In most studies, PDE5 inhibitors were shown to effectively and safely improve erectile function regardless of cause, severity, or presence of comorbid conditions, including hypertension, diabetes mellitus, and dyslipidemia.


Related Articles

  • Dyslipidemia Is a Strong Predictor of Vascular Dysfunction in Hispanic Children at Risk for Cardiovascular Disease. Lynch, Jane; Swamy, Anita; Patel, Shreya; Wajcberg, Estela; Defronzo, Ralph; Cersosimo, Eugenio; Hale, Daniel // Diabetes;Jun2007 Supplement 1, Vol. 56, pA231 

    Vascular dysfunction and lipid abnormalities are key pathophysiologic disturbances that occur early in the natural history of atherosclerosis. Individuals at risk for ASCVD commonly have positive family history (FH) of dyslipidemia, diabetes and/or hypertension, i.e., components of the metabolic...

  • Erectile Dysfunction and Undiagnosed Diabetes, Hypertension, and Hypercholesterolemia. Skeldon, Sean C.; Detsky, Allan S.; Goldenberg, S. Larry; Law, Michael R. // Annals of Family Medicine;Jul/Aug2015, Vol. 13 Issue 4, p331 

    PURPOSE We investigated whether erectile dysfunction, a marker for future cardiovascular disease, is associated with undiagnosed cardiometabolic risk factors among US men. Identifying the presence of these risk factors could lead to earlier initiation of treatment for primary prevention of...

  • ERECTILE DYSFUNCTION OF VASCULAR CAUSE. COELHO, M. Ferreira; SANTOS, P. Bargão // Acta Medica Portuguesa;SUP2011, Vol. 24 Issue S2, p379 

    Introduction: The Plurimetabolic Syndrome is a clustering of vascular risk factors (dyslipemia, abdominal perimeter, HTA and impaired glucose tolerance) with great importance in the development of cardiovascular disease (CVD) and diabetes (DM). CDV and DM are responsible for near 70% of the...

  • Cardiovascular problems common in men with erectile dysfunction. Guthrie, Ellen Whippie // Pharmacy Today;Apr2006, Vol. 12 Issue 4, p4 

    The article examines the association between cardiovascular disease and erectile dysfunction (ED). The risk factors common in men with ED include smoking, diabetes, hypertension, and others. Though medical treatment is required in ED, certain life style changes can decrease the incidence of the...

  • Prevention of chronic kidney and vascular disease: Toward global health equity—The Bellagio 2004 Declaration. Dirks, John H.; de Zeeuw, Dick; Agarwal, Sanjay K.; Atkins, Robert C.; Correa-Rotter, Ricardo; D'Amico, Giuseppe; Bennett, Peter H.; El Nahas, Meguid; Valdes, Raul Herrera; Kaseje, Dan; Katz, Ivor J.; Naicker, Sarala; Rodriguez-Iturbe, Bernardo; Schieppati, Arrigo; Shaheen, Faissal; Sitthi-Amorn, Chitr; Solez, Kim; Viberti, Giancarlo; Remuzzi, Giuseppe; Weening, Jan J. // Kidney International Supplement;Sep2005, Issue 98, pS1 

    Prevention of chronic kidney and vascular disease: Toward global health equity—The Bellagio 2004 Declaration. Chronic kidney disease (CKD) not only reflects target organ injury in systemic vascular disease in the general population and in association with diabetes, hypertension, and...

  • Macrovascular: diabetes complications. Forde, Rita // World of Irish Nursing & Midwifery;Sep2006, Vol. 14 Issue 8, p47 

    The article focuses on the macrovascular complications associated with diabetes. It is said that macrovascular disease is a condition that is both a complication of diabetes and is complicated by diabetes. Diabetes results to cardiovascular (CV) damage and is an independent risk factor of CV...

  • ED, diabetes, and CV risk: Update on treatment, risk reduction. Walker, Charles; Suarez-Sarmiento, Alfredo // Urology Times;Jan2016, Vol. 44 Issue 1, p15 

    The article discusses the association of erectile dysfunction (ED) to diabetes and cardiovascular disease (CVD). It notes the high prevalence and severity of ED among men who have diabetes. It cites that damage to the vascular endothelium caused by diabetes results in decreased blood flow to the...

  • Independent Nurse: Clinical - Medical management of erectile dysfunction.  // GP: General Practitioner;6/26/2009, p27 

    The article offers information on erectile dysfunction (ED). It states that ED is oftenly caused due to some physical problem such as pelvic disruption, vascular disease, and diabetes mellitus. ED can also be considered as a symptom of cardiovascular disease. A chart suggesting medical...

  • Design of Second Generation Phosphodiesterase 5 Inhibitors. Palmer, Michael J.; Bell, Andrew S.; Fox, David N. A.; Brown, David G. // Current Topics in Medicinal Chemistry;Feb2007, Vol. 7 Issue 4, p405 

    The clinical significance of phosphodiesterase 5 (PDE5) inhibition is increasingly understood following the pioneering work with sildenafil, and the continuing development programmes for both sildenafil and other marketed inhibitors. Since the initial launch of sildenafil for male erectile...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics